Usted buscó: refrattorja (Maltés - Inglés)

epilessija refrattorja
refractory epilepsy

ipokalemja refrattorja, iperkalċemja.
refractory hypokalaemia, hypercalcaemia

ipokalimja refrattorja, iponatrimija, iperkalċimja u iperuriċemija sintomatika.
refractory hypokalaemia, hyponatraemia, hypercalcaemia and symptomatic hyperuricaemia.

ipokalimja refrattorja, iponatrimija, iperkalċimija, u iperuriċemija sintomatika.
refractory hypokalaemia, hyponatraemia, hypercalcaemia, and symptomatic hyperuricaemia.

effikaċja klinika f’majeloma multipla li rkadiet jew refrattorja
clinical efficacy in relapsed or refractory multiple myeloma

id-dbm hija prinċipalment użata fl-industrija refrattorja sabiex tagħmel refrazzjonijiet iffurmati u mhux iffurmati.
dbm is mainly used in the refractory industry to make formed and unformed refractories.

studju 1, kien studju partikulari fuq 54 pazjent, li reġa ’ kellhom limfoma follikulari refrattorja wara kura b’ rituximab.
study 1 was a single arm study of 54 patients with relapsed follicular lymphoma refractory to rituximab treatment.

nucala hu indikat bħala kura supplimentali għal ażżma esinofilika refrattorja severa f’pazjenti adulti (ara sezzjoni 5.1).
nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients (see section 5.1).

nucala għandu jiġi preskritt lill-pazjenti minn tobba esperjenzati fid-dijanjożi u l-kura ta’ ażżma esinofilika refrattorja severa.
nucala should be prescribed by physicians experienced in the diagnosis and treatment of severe refractory eosinophilic asthma.

effikaċja klinika bl-għoti taħt il-ġilda ta’ bortezomib f’pazjenti b’majeloma multipla li tirkadi/refrattorja
clinical efficacy with subcutaneous administration of bortezomib in patients with relapsed/refractory multiple myeloma

effikaċja klinika bl-għoti taħt il-ġilda ta’ bortezomib f’pazjenti b’majeloma multipla li reġgħet tfaċċat/refrattorja
clinical efficacy with subcutaneous administration of bortezomib in patients with relapsed/refractory multiple myeloma

neorecormon għandu jintuża b’kawtela meta jkun hemm anemija refrattorja b’eċċess ta’ blasts li jkunu għadhom qed jiffurmaw, epilessija, tromboċitosi u insuffiċjenza kronika tal-fwied.
neorecormon should be used with caution in the presence of refractory anaemia with excess blasts in transformation, epilepsy, thrombocytosis, and chronic liver failure.